Vision
We aim to redefine cancer drug discovery by transforming cutting-edge science into breakthrough therapies.
We are strategically focused on addressing the high unmet needs in oncology and overcoming the limitations of current treatments.
This is achieved by developing novel therapeutic modalities that target hard-to-treat cancers with distinct mechanisms.
Critically, our development strategy emphasizes a patient-centric design, prioritizing therapies to ensure improved patient compliance, ease of administration, and greater accessibility.
Founder | CEO
Arun is a serial biotech entrepreneur and previously co-founded Aten Porus Lifesciences and Oraxion Therapeutics, both drug discovery companies. Arun holds an MBA from the Royal Melbourne Institute of Technology, and a Bachelors of Science from Christ University. He has over 15 years experience in finance, operations, technology transfer and business development. Arun was instrumental in the option agreement of Oraxion’s technology platform to a US based biotech company for $125M.
Founder | CSO
Aditya previously co-founded Aten Porus Lifesciences and Oraxion Therapeutics. He is also the inventor of Oraxion’s technology platform that was eventually licensed to a US based biotech company for $125 MM. Aditya earned a PhD in Bioorganic Chemistry from Purdue University and was awarded the H. C. Brown Award for Outstanding Organic Research. He has co-authored >20 papers and filed several international patents in the areas of nucleic acid delivery, Niemann-Pick Type C therapeutics, and drug discovery.
Founder | Director
Srinivasan previously co-founded Aten Porus Lifesciences and Oraxion Therapeutics, and was instrumental in Aten’s exit to Bain Private Equity in 2023. He is a prolific investor with diverse investments across spacetech, deeptech, healthcare, and D2C sectors. Srinivasan holds a Masters in Pharmaceutics from Northeastern University, and a Bachelors in Pharmacology from BITS Pilani. He has over 20 years of experience in technology transfer, SCM, business development and finance.
Associate Director | R&D
Sandeep is a medicinal chemist with over a decade of experience in NCE design, synthesis, and structure-/ligand-based drug discovery. He has deep expertise in advanced molecular modelling and in the multi-step synthesis of NCEs and natural products. Sandeep earned his Ph.D. in Medicinal Chemistry from NIPER Mohali.
Senior Manager | R&D
Avijit is a biochemist and immunologist by training with over 8 years of experience in RNA biology, host-pathogen interactions, and immune modulation in infectious diseases and cancer. He holds a Ph.D. in Biochemistry during which he elucidated novel roles of RNA-binding proteins and miRNAs in macrophage immunology and pathogenesis.
Program Manager and Team Lead | R&D
Princy has over 11 years of experience in preclinical R&D and drug discovery program management. Her expertise spans data-driven decision-making, competitive landscape analysis and strategic program execution. She holds a Masters in Analytical Chemistry, and brings scientific and operational insight to early-stage drug development.
Sr Manager | Accounts and Administration
Sunny has over 14 years of experience in accounts, finance, and administrative operations. As Senior Manager – Accounts & Administration, his expertise spans strategic financial planning, budgeting and forecasting, regulatory compliance, and internal audit oversight. He brings strong capabilities in financial reporting, policy development, resource allocation, and workflow optimization, consistently improving cross-functional efficiency and governance. Sunny holds a Master’s degree in Finance from Alagappa University, Tamil Nadu, India, and combines financial rigor with operational excellence.
We are guided by global leaders in innate immunology, medicinal chemistry, oncology and translational science.
